| TIL Stock | | | USD 8.75 -0.28 -3.10% |
This math transform tool runs Inverse Tangent Over Price Movement transformation and companion studies for Instil Bio. It emphasizes price transformations that reveal shifts in trend structure while keeping volatility, risk, and performance context in view.
Most technical analysis of Instil Bio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Instil from various momentum indicators to cycle indicators. When you analyze Instil charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 463 people. Liquidity and trading activity can influence how quickly new information is reflected in Instil Bio's price. Lower trading activity may introduce occasional variability in execution conditions. Instil Bio has a market cap of 61.24 M, P/E of 18.31, ROE of -50.6%.
Methodology
Unless otherwise specified, financial data for Instil Bio is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Instil (USA Stocks:TIL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Instil Bio may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board
Tracking Instil Bio inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.